Infinity Pharmaceuticals Financial Diagnostics

Infinity Pharmaceuticals Inc -- USA Stock  

USD 2.3  0.02  0.88%

Infinity Pharmaceuticals Inc diagnostics interface makes it easy to digest most current publicly released information about Infinity Pharmaceuticals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Infinity Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.
About 71.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Infinity Pharmaceuticals Inc recorded loss per share of 1.39. This company had not issued any dividends in recent years. The firm had 1:4 split on 2006-09-13. Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficulttotreat diseases. To learn more about INFINITY PHARMACE call Adelene Perkins at 617-453-1000 or check out www.infi.com.

Infinity Pharmaceuticals Alerts

Infinity Pharmaceuticals appears to be very risky and stock price may revert if volatility continues
Infinity Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 0. Net Loss for the year was (69.61 M) with profit before overhead, payroll, taxes, and interest of 18.72 M.
INFINITY PHARMACE currently holds about 66.2 M in cash with (82.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31.
Roughly 71.0% of the company shares are owned by institutional investors
Latest headline from www.stocknewsjournal.com: Buy or Sell Average Brokerage Ratings on Chevron Corporation , Infinity ...

Infinity Pharmaceuticals Upcoming Events

Upcoming Quarterly ReportFebruary 28, 2017
Next Earnings ReportMay 3, 2017

Infinity Pharmaceuticals EPS Estimate

EPSEstimate Date
Quarterly Estimate-0.56February 28, 2017

Infinity Pharmaceuticals SEC Filings

Financial Statements and Exhibits. Other Events
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Results of Operations and Financial Condition
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition

Institutional Investors

Security TypeSharesValue
Acadian Asset Management LlcCommon Shares37 K49 K
Meeder Asset Management IncCommon Shares2.6 K4 K
American Financial Network Advisory Services LlcCommon Shares1280.0
Bvf IncCommon Shares7.9 M12.3 M
Wellington Management Group LlpCommon Shares4.7 M7.4 M
Vanguard Group IncCommon Shares4.6 M7.3 M
Orbimed Advisors LlcCommon Shares3.3 M5.1 M

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 115.57 M.

Management Efficiency

Infinity Pharmaceuticals Inc has return on total asset (ROA) of (26.58) % which means that it has lost $26.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (78.61) % meaning that it created substantial loss on money invested by shareholders.

Stock Holders for Infinity Pharmaceuticals

Information
Ratio
Value
At Risk
NASDAQNASDAQ Composite Total Return I 0.00  0.00 
NasdaqNasdaq(0.12) (0.29) 
JC PenneyJ C Penney Company Inc(0.21) (4.31) 
ItocoItoco Mining Corporation 0.15 (50) 
FTRFrontier Communications Corporation(0.11) (2.7) 
CannabisCannabis Science Inc(0.0899) (25) 
AdvantisAdvantis Corp 0.00  0.00 
XNBINASDAQ Biotechnology Total Retu(0.34) (1.06) 
NYSENYSE(0.48) (0.19) 

Technical Drivers

Infinity Pharmaceuticals Inc retains Downside Deviation of 11.7, Market Risk Adjusted Performance of (0.13) and Risk Adjusted Performance of 0.0633. Infinity Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with intention to determine a pattern that calculates the direction of the corporation future prices. In other words you can use this information to find out if the corporation will indeed mirror its model of historical price patterns or the prices will eventually revert. We found nineteen technical drivers for Infinity Pharmaceuticals which can be compared to its competitors. Please check out Infinity Pharmaceuticals Treynor Ratio, and the relationship between Standard Deviation and Downside Variance to decide if Infinity Pharmaceuticals is priced fairly providing market reflects its last-minute price of 2.3 per share. Please also validate Infinity Pharmaceuticals Total Risk Alpha which is currently at (13.49) to confirm the company can sustain itself at future point.

Stakeholder Activities

Infinity Pharmaceuticals Insider Trading

Predictive Analysis

Infinity Pharmaceuticals Predictive Indicators

Corporate Filings

Infinity Pharmaceuticals Corporate Reports
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations